Although the current understanding of the pathophysiological mechanisms of mood disorders and depression has changed to include monoamine deficiency, impaired neurogenesis, inflammation, and genetics, VMAT2 inhibition by reserpine remains a valid model of depression in preclinical animal models [37, 38]. Here, SLC18A2 is linked to depressive symptom measurement.